Therachon

Therachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is significant unmet medical need. We are currently advancing a pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions. Our lead product candidate, apraglutide, is a second generation, potentially best-in-class, synthetic peptide analog of glucagon-like peptide-2, or GLP-2, that is being evaluated in two Phase 2 clinical trials for the treatment of patients with short bowel syndrome, or SBS, a malabsorption disorder caused by the loss of functional small intestine. Our second product candidate, TA-46, has completed a Phase 1 clinical trial and is designed to address the root molecular cause of achondroplasia, a rare genetic condition and the most common form of short-limbed dwarfism in humans. View our social media community guidelines here: http://bit.ly/2TdB4Vm.